AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3284133 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin/Dihydroergotamine (HDHE)
Number of subjects: 212
Study 3284133 — intervention group
Group type: COMPARATOR
Intervention: Heparin/Acenocoumarin (Hep/S)
Number of subjects: 212
Study 29347996 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate per day (4 over-encapsulated tablets)
Number of subjects: 200
Study 29347996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 29347996 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 200
Study 27057866 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 762
Study 27057866 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 762
Study 24482677 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension (468±88 days) with lifestyle modifications
Number of subjects: 121
Study 24344672 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose antibiotic impregnated cement (1 gram Clindamycin and 1 gram Gentamicin)
Number of subjects: 848
Study 24344672 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 848
Study 20664388 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal colpopexy repair with mesh (32 women, 24 anterior mesh, 8 total mesh)
Number of subjects: 65
Study 20664388 — intervention group
Group type: COMPARATOR
Intervention: Traditional vaginal colpopexy without mesh (33 women)
Number of subjects: 65
Study 20664388 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal colpopexy repair with mesh
Number of subjects: 65
Study 20664388 — intervention group
Group type: COMPARATOR
Intervention: Traditional vaginal colpopexy without mesh
Number of subjects: 65
Study 20664388 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal colpopexy repair with mesh and traditional vaginal colpopexy without mesh
Number of subjects: 65
Study 19090407 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) injection (5 microg in 0.2 mL)
Number of subjects: 14
Study 19090407 — intervention group
Group type: COMPARATOR
Intervention: Buffered isotonic saline (control, 0.2 mL)
Number of subjects: 14
Study 16632022 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback dialysis
Number of subjects: 8
Study 16632022 — intervention group
Group type: COMPARATOR
Intervention: Standard hemodialysis (HD)
Number of subjects: 8
Study 14983954 — intervention group
Group type: EXPERIMENTAL
Intervention: Active screening (testing prostate-specific antigen, PSA)
Number of subjects: 10300
Study 14983954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10300
Study 11058851 — intervention group
Group type: EXPERIMENTAL
Intervention: Radially expanding trocars (group S)
Number of subjects: 250
Study 11058851 — intervention group
Group type: COMPARATOR
Intervention: Conventional cutting trocars (group C)
Number of subjects: 250
Study 11058851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study 9387731 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangshenkang (TSK) capsule
Number of subjects: 57
Study 9387731 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 57
Study 1415946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral examination performance (grouped as honors, high satisfactory, satisfactory, unsatisfactory)
Number of subjects: 0
Study 1415946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral examination groups throughout the rotations
Number of subjects: 0
Study 2991478 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus methanol extractable residue of BCG (MER-BCG)
Number of subjects: 0
Study 2991478 — intervention group
Group type: COMPARATOR
Intervention: No MER-BCG
Number of subjects: 0
Study 31211392 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning (fasting) resistance exercise
Number of subjects: 12
Study 31211392 — intervention group
Group type: COMPARATOR
Intervention: Afternoon resistance exercise
Number of subjects: 12
Study 30010061 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin monotherapy (loading dose of 9 MIU followed by 3 MIU every 8 hours)
Number of subjects: 60
Study 30010061 — intervention group
Group type: COMPARATOR
Intervention: Colistin + meropenem combination therapy (colistin 8.58 MIU and meropenem 1 g every 8 hours for 15 days)
Number of subjects: 60
Study 26234801 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioural therapy (CBT)
Number of subjects: 58
Study 23829297 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotics (Bifidobacterium longum, B. bifidum, B. lactis, Lactobacillus acidophilus, L. rhamnosus, and Streptococcus thermophilus) twice a day for 4 weeks
Number of subjects: 49
Study 23829297 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice a day for 4 weeks
Number of subjects: 49
Study 23829297 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotics
Number of subjects: 49
Study 23829297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 22545019 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone lateral interbody fusion
Number of subjects: 52
Study 20577119 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 9309
Study 20577119 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 9309
Study 20577119 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 9309
Study 20577119 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE I/D polymorphism (rs1799752)
Number of subjects: 9309
Study 20577119 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE promoter polymorphism (‐262, rs4291)
Number of subjects: 9309
Study 20577119 — intervention group
Group type: EXPERIMENTAL
Intervention: SCNN1A (rs2228576)
Number of subjects: 9309
Study 17392658 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 0
Study 17392658 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0
Study 17392658 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 0
Study 17392658 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 15604119 — intervention group
Group type: EXPERIMENTAL
Intervention: Program participants
Number of subjects: 157
Study 15604119 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study 11851788 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 25
Study 11851788 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided relaxation
Number of subjects: 25
Study 11851788 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study 9656503 — intervention group
Group type: EXPERIMENTAL
Intervention: Doula support
Number of subjects: 35
Study 9656503 — intervention group
Group type: COMPARATOR
Intervention: Lamaze preparation
Number of subjects: 35
Study 7625503 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermicidal foam
Number of subjects: 264
Study 7625503 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermicidal suppositories
Number of subjects: 264
Study 7625503 — intervention group
Group type: EXPERIMENTAL
Intervention: Foaming tablets
Number of subjects: 264
Study 7625503 — intervention group
Group type: COMPARATOR
Intervention: Control group (no spermicide use)
Number of subjects: 264
Study 2551622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (400 mg)
Number of subjects: 12
Study 2551622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 321184 — intervention group
Group type: EXPERIMENTAL
Intervention: oxpentifylline (200 mg 3-times a day)
Number of subjects: 20
Study 321184 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 31812289 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver resection (LR)
Number of subjects: 154
Study 31812289 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CTx)
Number of subjects: 154
Study 30852939 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI7510 (adjuvanted RSV sF vaccine)
Number of subjects: 45
Study 30852939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 27567020 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital Atherectomy System (OAS) treatment in patients with eGFR < 90 ml/min/1.73 m2
Number of subjects: 443
Study 27567020 — intervention group
Group type: EXPERIMENTAL
Intervention: Orbital Atherectomy System (OAS) treatment in patients with eGFR ≥ 90 ml/min/1.73 m2
Number of subjects: 443
Study 24961535 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium abutments and porcelain-fused-to-metal crowns
Number of subjects: 11
Study 24961535 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia abutments and ceramic crowns
Number of subjects: 11
Study 24961535 — intervention group
Group type: COMPARATOR
Intervention: Gingiva of the neighbouring teeth
Number of subjects: 11
Study 23547848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg (s.c.)
Number of subjects: 48
Study 23547848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 81 mg (s.c.)
Number of subjects: 48
Study 23547848 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab (i.v.)
Number of subjects: 48
Study 21736720 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care program (watchful waiting, guided self‐help, short face‐to‐face problem solving treatment, pharmacotherapy and/or specialized mental health care)
Number of subjects: 120
Study 21736720 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 120
Study 19857803 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced CT colonography (CECTC)
Number of subjects: 29
Study 19857803 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic colonoscopy (EC)
Number of subjects: 29
Study 16670248 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer disease (AD) patients
Number of subjects: 163
Study 16670248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively impaired nondemented (CIND) individuals
Number of subjects: 163
Study 16670248 — intervention group
Group type: COMPARATOR
Intervention: Total NPI scores
Number of subjects: 163
Study 16670248 — intervention group
Group type: COMPARATOR
Intervention: Apathy
Number of subjects: 163
Study 15048550 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 11
Study 15048550 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 11
Study 10986540 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE chemotherapy plus G‐CSF (granulocyte colony‐stimulating factor) at 2‐week intervals
Number of subjects: 0
Study 10986540 — intervention group
Group type: COMPARATOR
Intervention: ACE chemotherapy alone at standard 3‐week intervals
Number of subjects: 0
Study 9076616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg) three times daily for 4 weeks
Number of subjects: 104
Study 9076616 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily for 4 weeks
Number of subjects: 104
Study 8401051 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethylamine oral challenge (600 mg)
Number of subjects: 187
Study 8401051 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical tests for trimethylamine and trimethylamine N‐oxide
Number of subjects: 187
Study 8401051 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial assessment
Number of subjects: 187
Study 3533243 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood culture obtained (67 children)
Number of subjects: 146
Study 3533243 — intervention group
Group type: COMPARATOR
Intervention: No blood culture obtained (79 children)
Number of subjects: 146
Study 3045026 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (200 mg/day, intramuscular)
Number of subjects: 20
Study 3045026 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 20
Study 30928117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Health Composite score
Number of subjects: 176
Study 28377492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening for lung cancer, annual invitation for 4 years
Number of subjects: 3206
Study 28377492 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening for lung cancer
Number of subjects: 3206
Study 28377492 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3206
Study 25588664 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm tourniquet
Number of subjects: 100
Study 25588664 — intervention group
Group type: COMPARATOR
Intervention: Forearm tourniquet
Number of subjects: 100
Study 23715925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g intravenously 15-45 min before skin incision
Number of subjects: 874
Study 23715925 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone after cord clamping
Number of subjects: 874
Study 22196238 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE‐II score on day 1
Number of subjects: 221
Study 22196238 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score on day 2
Number of subjects: 221
Study 18395725 — intervention group
Group type: EXPERIMENTAL
Intervention: Presacral neurectomy
Number of subjects: 0
Study 18395725 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine nerve ablation
Number of subjects: 0
Study 17056359 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySofIQ IOL
Number of subjects: 120
Study 17056359 — intervention group
Group type: COMPARATOR
Intervention: AcrySofNatural IOL
Number of subjects: 120
Study 17056359 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 120
Study 12604972 — intervention group
Group type: EXPERIMENTAL
Intervention: New infant formula (NF)
Number of subjects: 154
Study 12604972 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 154
Study 11050580 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (1 mg/kg) + Vitamin E (800 IU/day)
Number of subjects: 140
Study 11050580 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin (1 mg/kg) + Vitamin E placebo
Number of subjects: 140
Study 9148645 — intervention group
Group type: EXPERIMENTAL
Intervention: Evastin
Number of subjects: 56
Study 9148645 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastin
Number of subjects: 56
Study 9148645 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 56
Study 8265524 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin with triazolam
Number of subjects: 0
Study 8265524 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin with triazolam
Number of subjects: 0
Study 8265524 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin with midazolam 5 mg
Number of subjects: 0
Study 8265524 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 10 mg with erythromycin
Number of subjects: 0
Study 8265524 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 10 mg with roxithromycin
Number of subjects: 0
Study 8265524 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 15 mg
Number of subjects: 0
Study 2872056 — intervention group
Group type: EXPERIMENTAL
Intervention: diacetolol 600 mg
Number of subjects: 11
Study 2872056 — intervention group
Group type: EXPERIMENTAL
Intervention: acebutolol 400 mg
Number of subjects: 11
Study 2872056 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol 200 mg
Number of subjects: 11
Study 2872056 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol 80 mg
Number of subjects: 11
Study 2872056 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 30462720 — intervention group
Group type: COMPARATOR
Intervention: Insulin resistance (IR)
Number of subjects: 106
Study 30462720 — intervention group
Group type: COMPARATOR
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 106
Study 30462720 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoglycemic (CTRL)
Number of subjects: 106
Study 26839716 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Rehabilitation (FS)
Number of subjects: 12
Study 26839716 — intervention group
Group type: COMPARATOR
Intervention: Nonfunctional Rehabilitation (NFS)
Number of subjects: 12
Study 25397825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (8 sessions of 60 minutes each, twice weekly)
Number of subjects: 55
Study 25397825 — intervention group
Group type: COMPARATOR
Intervention: Usual PTSD care (UPC)
Number of subjects: 55
Study 25397825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 55
Study 22915053 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (200 mg/m² on days 1-5) and Bevacizumab (10 mg/kg on days 1 and 15) every 28 days (Regimen TB)
Number of subjects: 93
Study 22915053 — intervention group
Group type: COMPARATOR
Intervention: Nab-paclitaxel (100 mg/m² or 80 mg/m² post-addendum on days 1, 8, and 15), Bevacizumab (10 mg/kg on days 1 and 15), and Carboplatin (AUC 6 on day 1 or AUC 5 post-addendum) every 28 days (Regimen ABC)
Number of subjects: 93
Study 20860546 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX‐IL8 (fully human IgG₂ monoclonal antibody)
Number of subjects: 0
Study 20860546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18822011 — intervention group
Group type: EXPERIMENTAL
Intervention: Microseal
Number of subjects: 60
Study 18822011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Compaction (LC)
Number of subjects: 60
Study 18822011 — intervention group
Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 60
Study 18822011 — intervention group
Group type: EXPERIMENTAL
Intervention: JS Quick‐Fill
Number of subjects: 60
Study 18822011 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil
Number of subjects: 60
Study 18822011 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft Core
Number of subjects: 60
Study 16647911 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole vaginal gel (0.75%)
Number of subjects: 157
Study 16647911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 12444307 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 6595
Study 12444307 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 6595
Study 10196830 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-welded titanium frameworks
Number of subjects: 824
Study 10196830 — intervention group
Group type: COMPARATOR
Intervention: Conventional gold-alloy castings (Control)
Number of subjects: 824
Study 10196830 — intervention group
Group type: EXPERIMENTAL
Intervention: Both titanium frameworks and control group
Number of subjects: 824
Study 10196830 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium frameworks
Number of subjects: 824
Study 7594126 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual-protein diet
Number of subjects: 0
Study 7594126 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 0
Study 7594126 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-protein diet
Number of subjects: 0
Study 7594126 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of protein intake
Number of subjects: 0
Study 7594126 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback by the dietitian
Number of subjects: 0
Study 2339625 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25‐(OH)2D3 2 micrograms/day for 2 weeks before 3 months of sodium fluoride treatment 25 mg twice a day, in each 5‐month cycle
Number of subjects: 71
Study 2339625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) 25 mg twice a day with 1,25‐(OH)2D3 0.5 micrograms/day for 12 months in each 13‐month cycle
Number of subjects: 71
Study 2339625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF) combined with calcium citrate for 12 months in each 13‐month cycle
Number of subjects: 71
Study 2339625 — intervention group
Group type: COMPARATOR
Intervention: All groups (including sodium fluoride treatment)
Number of subjects: 71
Study 2339625 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride treatment
Number of subjects: 71
Study 6107057 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.4‐0.8 mg)
Number of subjects: 0
Study 6107057 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoctamine (10‐20 mg)
Number of subjects: 0
Study 6107057 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 0
Study 30134428 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out HIV screening during pregnancy
Number of subjects: 0
Study 30134428 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat HIV testing in the third trimester
Number of subjects: 0
Study 30134428 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid HIV screening during labor and delivery
Number of subjects: 0
Study 30134428 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral prophylaxis initiation
Number of subjects: 0
Study 30134428 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to ongoing care with HIV specialist
Number of subjects: 0
Study 26824722 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-manual lymph drainage (MLD) combined with physical exercise
Number of subjects: 1000
Study 26824722 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise (PE) only
Number of subjects: 1000
Study 25407038 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational presentation on human trafficking (HT)
Number of subjects: 258
Study 25407038 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention comparison group
Number of subjects: 258
Study 21614529 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing threatening and deviant/violent life events
Number of subjects: 515
Study 21614529 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of adverse life events experienced
Number of subjects: 515
Study 20354472 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc‐C cervical disc replacement (CDR)
Number of subjects: 164
Study 17684166 — intervention group
Group type: EXPERIMENTAL
Intervention: Resiliency training classes
Number of subjects: 67
Study 17684166 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 67